NUREXONE BIOLOGIC INC. (J90) — Cash Flow-to-Debt Ratio
NUREXONE BIOLOGIC INC. (J90) has a Cash Flow-to-Debt Ratio of -0.89x as of December 2025, meaning its operating cash flow of €-1.17 Million could theoretically repay -1% of its total liabilities (€1.32 Million) in one year. See NUREXONE BIOLOGIC INC. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NUREXONE BIOLOGIC INC. Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for NUREXONE BIOLOGIC INC. across 5 annual periods. Also explore how fast is NUREXONE BIOLOGIC INC. growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NUREXONE BIOLOGIC INC. (2021–2025)
Year-by-year debt coverage analysis for NUREXONE BIOLOGIC INC.. For market capitalisation and broader financial context, see NUREXONE BIOLOGIC INC. (J90) total market value.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.40x | €-4.51 Million | €1.32 Million | ▲ +52.6% |
| 2024 | -7.19x | €-4.89 Million | €680.00K | ▼ -384.2% |
| 2023 | -1.48x | €-2.94 Million | €1.98 Million | ▲ +73.1% |
| 2022 | -5.51x | €-3.85 Million | €698.00K | ▼ -642.4% |
| 2021 | -0.74x | €-1.23 Million | €1.66 Million | — |